目的观察质量分数1%阿托品对豚鼠形觉剥夺性近视(FDM)进展的防控作用及其潜在的生物学机制。
方法选取屈光状态正常的3周龄三色豚鼠69只,采用随机数字表法将其随机分为正常对照组19只、FDM模型组19只、FDM+阿托品组19只和阿托品组12只。采用半透明乳胶气球遮盖右眼的方法建立FDM模型,正常对照组不进行实验干预;FDM模型组单纯遮盖右眼4周;FDM+阿托品组遮盖右眼4周,同时每日使用1%阿托品凝胶点眼1次;阿托品组每日使用1%阿托品凝胶点眼1次,共4周。分别于实验前、实验2周和实验4周时采用带状光检影镜进行屈光度测定,采用眼科A型超声仪测量眼轴长度。实验4周时采集完整眼球制作石蜡切片,光学显微镜下观察巩膜组织形态学变化;采集后极部巩膜组织,透射电子显微镜下观察巩膜组织超微结构变化;采用相对和绝对定量同位素标记(iTRAQ)联合液相色谱-串联质谱(LC-MS/MS)技术进行巩膜组织蛋白质质谱检测。
结果正常对照组、FDM模型组、FDM+阿托品组和阿托品组实验眼不同时间点屈光度总体比较,差异均有统计学意义( F 分组=138.892, P<0.001; F 时间=167.270, P<0.001),其中FDM模型组实验2周和4周、FDM+阿托品组实验4周较正常对照组屈光度向近视化方向发展,实验2周和4周FDM+阿托品组较FDM模型组屈光度向远视化方向发展,屈光度比较差异均有统计学意义(均 P<0.001)。正常对照组、FDM模型组、FDM+阿托品组和阿托品组实验眼不同时间点眼轴长度总体比较差异均有统计学意义( F 分组=32.346, P<0.001; F 时间=353.797, P<0.001),其中FDM模型组实验2周和4周、FDM+阿托品组实验4周眼轴长度均长于相应时间点正常对照组,FDM+阿托品组实验2周和4周眼轴长度均短于相应时间点FDM模型组,差异均有统计学意义(均 P<0.01)。FDM模型组豚鼠后极部巩膜胶原纤维排列疏松且紊乱,FDM+阿托品组后极部巩膜胶原纤维排列较规则。正常对照组、FDM模型组、FDM+阿托品组和阿托品组后极部巩膜厚度值分别为(141.74±16.98)、(101.46±9.15)、(112.74±6.24)和(134.30±18.19)μm,总体比较差异有统计学意义( F=6.709, P=0.005),其中FDM模型组后极部巩膜厚度明显小于正常对照组和FDM+阿托品组,差异均有统计学意义(均 P<0.05)。正常对照组、FDM+阿托品组和阿托品组后极部巩膜胶原纤维直径从内到外逐渐增大,FDM模型组后极部巩膜组织内、中、外层纤维直径均较正常对照组减小。巩膜组织蛋白质组学分析发现,FDM模型组与正常对照组以及FDM+阿托品组与FDM模型组间差异倍数均在1.30倍及以上的蛋白85个,其中阿托品干预上调蛋白38个,下调蛋白47个。GO富集分析发现,生物过程主要涉及生物调节、细胞过程、定位及代谢过程等,分子功能主要涉及结合、催化活性、分子功能调控、分子活性及转运活性等,细胞成分主要涉及细胞解剖实体、细胞内物质及含蛋白的复合体。
结论阿托品可增加FDM模型豚鼠巩膜胶原纤维直径,改善胶原纤维排列,抑制巩膜变薄,其控制近视进展的机制可能与巩膜细胞间紧密连接、细胞骨架和细胞外基质重塑密切相关。
ObjectiveTo observe the prevention and control effect of 1% atropine on the progression of form deprivation myopia (FDM) in guinea pigs and the potential biological mechanism.
MethodsSixty-nine 3-week-old tricolor guinea pigs with normal refraction were randomly divided into a normal control group ( n=19), a FDM group ( n=19), a FDM+ atropine group ( n=19), and an atropine group ( n=12). No intervention was given to guinea pigs in normal control group.The FDM model was established by covering the right eye of guinea pigs with a semitransparent latex facemask for 4 weeks in FDM and FDM+ atropine groups.For the FDM+ atropine group, 1% atropine gel was topically administered to the form-deprived right eyes once a day for 4 weeks.For the atropine group, the right eye was treated with 1% atropine gel once a day for 4 weeks.Refraction and axial length of guinea pigs were measured by retinoscopy and ophthalmic A-scan ultrasonography respectively at baseline, experiment week 2 and week 4.In experiment week 4, eyeballs were enucleated to make sections via the paraffin wax processing procedure, and the microstructural and ultrastructural changes of the sclera were observed under the light microscope and transmission electron microscope, respectively.The isobaric tags for relative and absolute quantitation labeling combined with liquid chromatography-tandem mass spectrometry were used to identify the differentially expressed proteins.Use and care of the animals complied with the Regulation for the Administration of Affairs Concerning Experiment Animals by State Science and Technology Commission.The study protocol was approved by the Institutional Animal Care and Use Committee of Tianjin Medical University (No.TJYY2020111028).
ResultsThere were statistically significant differences in the diopter of guinea pigs at different time points among the four groups ( F group=138.892, P<0.001; F time=167.270, P<0.001). Compared with normal control group, the diopter of guinea pigs in FDM group at experiment weeks 2 and 4, and FDM+ atropine group at experiment week 4 developed toward myopia, showing statistically significant differences (all at P<0.001). Compared with FDM group, the diopter of guinea pigs in FDM+ atropine group at experiment weeks 2 and 4 developed toward hyperopia, showing statistically significant differences (both at P<0.001). There were statistically significant differences in the axial length of guinea pigs at different time points among the four groups ( F group=32.346, P<0.001; F time=353.797, P<0.001). The axial lengths of FDM group at experiment weeks 2 and 4 and FDM+ atropine group at experiment week 4 were longer than those of normal control group, and the axial lengths in FDM+ atropine group at experiment weeks 2 and 4 were shorter than those in FDM group, and the differences were statistically significant (all at P<0.001). The collagenous fibers of posterior sclera of guinea pigs were loose and disordered in FDM group, and were regular in FDM+ atropine group.The posterior scleral thickness of normal control group, FDM group, FDM+ atropine group and atropine group was (141.74±16.98), (101.46±9.15), (112.74±6.24) and (134.30±18.19) μm, respectively, with a statistically significant difference ( F=6.709, P=0.005). The posterior sclera was significantly thinner in FDM group than in normal control group and FDM+ atropine group (both at P<0.05). The diameter of posterior scleral collagen fiber gradually increased from inside to outside in normal control group, FDM+ atropine group and atropine group, and the diameters of the inner, middle and outer posterior scleral collagen fibers were smaller in FDM group than in normal control group.Proteomic analysis revealed 85 differentially expressed proteins (fold change>1.30) between FDM group and normal control group, FDM+ atropine group and FDM group, of which 38 were up-regulated and 47 were down-regulated after atropine treatment.Gene Ontology enrichment analysis showed that biological processes mainly involved were biological regulation, cell process, localization and metabolic process.Molecular function mainly involved were binding, catalytic activity, molecular function regulator, structural molecule activity and transporter activity.Cell components mainly involved were in cellular anatomical entity, intracellular and protein-containing complex.
ConclusionsAtropine can increase the diameter of scleral collagen fibers in guinea pigs of FDM model, improve the arrangement of scleral collagen fiber, inhibit scleral thinning.The mechanism of atropine to control myopia progression is closely related to the tight junction between scleral cells, cytoskeleton and extracellular matrix remodeling.
嵇霄雯,宫博腾,祝颖,等. 1%阿托品对豚鼠形觉剥夺性近视进展的防控作用及其机制[J]. 中华实验眼科杂志,2023,41(04):303-311.
DOI:10.3760/cma.j.cn115989-20211026-00584版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
嵇霄雯:参与选题、研究实施、数据收集及整理分析、论文写作;宫博腾:参与选题、实施研究;祝颖:研究设计;鹿大千、刘勋:实施研究;刘琳、杜蓓:论文智力性内容修改;魏瑞华:参与选题、研究设计及定稿

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。